Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Olivier_Laureau
|
| gptkbp:country |
gptkb:France
|
| gptkbp:focusesOn |
gptkb:diabetes
cardiology oncology rheumatology neuropsychiatry |
| gptkbp:foundedBy |
gptkb:Jacques_Servier
|
| gptkbp:foundedYear |
1954
|
| gptkbp:hasResearchCenter |
16
|
| gptkbp:headquartersLocation |
Suresnes, France
|
| https://www.w3.org/2000/01/rdf-schema#label |
Servier Group
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
150 countries
|
| gptkbp:notableEvent |
gptkb:Mediator_scandal
|
| gptkbp:notableProduct |
gptkb:Valdoxan
gptkb:Diamicron gptkb:Perindopril Triplixam |
| gptkbp:numberOfEmployees |
22000
|
| gptkbp:operatesIn |
global
|
| gptkbp:productionSites |
16
|
| gptkbp:revenue |
4.9 billion euros (2022)
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://servier.com
|
| gptkbp:bfsParent |
gptkb:Servier_Laboratories
|
| gptkbp:bfsLayer |
7
|